Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can clearing old cells boost brain and body in MS? new trial aims to find out

NCT ID NCT07270120

Symptom relief Sponsor: Ohio State University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial tests whether a combination of two drugs, dasatinib and quercetin, can safely remove aged, damaged cells that may contribute to inflammation and nerve damage in people with secondary progressive multiple sclerosis (MS). The study enrolls 30 adults aged 50-85 who have not taken MS medications recently and have noticed worsening symptoms. Participants take the drugs every two weeks for three months and are followed for one year to see if their physical and cognitive function improves.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

About 30 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jan 2026

An estimate. Start dates often move.

Expected to finish

Jan 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

50 to 85 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Individuals aged 50-85 with SPMS diagnosed using the 2024 McDonald Criteria 2. Not treated with a DMT for MS within the last 6 months or have used alemtuzumab, cladribine, or mitoxantrone. 3. Evidence of MS progression over the past 12 months. Exclusion Criteria: 1. Unstable coronary artery disease (myocardial infarction within 6 months or angina) 2. Hospitalization within 6 months 3. Stroke or transient ischemic attack in the past 6 months 4. Pulmonary arterial hypertension 5. Current or chronic history of liver disease 6. Alzheimer's or Parkinson's disease 7. Drug or alcohol abuse in the previous 5 years 8. History of coagulation disorders, central nervous system hemorrhage, or gastrointestinal hemorrhage 9. History of angina or myocardial infarction, arrhythmia, or heart failure at any time 10. QTc prolongation 11. Anemia (Hgb\<9), thrombocytopenia (platelets\<50,000 per microliter), or neutropenia (ANC\< 1000 per microliter) 12. Moderate hypokalemia (2.9 mmol/L) and moderate hypomagnesemia (0.9-1.1 mg/dL or 0.37-0.45 mmol/L) 13. ALT/AST \>1.5x ULN, total bilirubin \>ULN, and alkaline phosphatase \>2x ULN 14. Chronic renal disease (glomerular filtration rate \< 30 mL/min/1.73 m2) 15. Alcohol intake greater than 2 drinks/day for men and greater than 1 drink/day for women 16. Anti-arrhythmic medications known to cause QTc prolongation 17. Antipsychotics and anxiolytics 18. Anti-platelet or anti-coagulant medications other than aspirin 19. Quinolone antibiotics 20. Pregnant or lactating subjects or subjects intending to become pregnant or to donate egg/sperm 21. Participants with p16INK4a below the median of SPMS patients in the OSU Aging and MS Cohort 22. Use of drugs metabolized by the same liver enzymes as D or Q

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Multiple sclerosis (MS) secondary progressive are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic progressive multiple sclerosis multiple sclerosis secondary progressive multiple sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Multiple sclerosis (MS) secondary progressive

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The study's own enquiry address

    This study publishes an address for enquiries. See it below .

  2. The places running it

    1 site. The list below names each one and where it is.

  3. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  4. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Ohio State Martha Morehouse Outpatient Care

    Columbus, Ohio, 43210, United States

    Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.